Shares of Gujarat Kidney & Super Speciality Ltd, a regional healthcare company based in Gujarat, made a strong debut on the National Stock Exchange (NSE) on Tuesday, December 30, 2025. The stock opened at ₹120 per share, about 5.26% above its IPO issue price of ₹114. On the Bombay Stock Exchange (BSE), shares listed at ₹120.75, showing a premium of nearly 5.92%. The initial listing gains reflect healthy investor demand and optimism around the company’s growth prospects.
For retail investors, the IPO offered an attractive opportunity. With a lot size of 128 shares, those allotted the minimum lot could have made a listing day gain of ₹15,360 by selling at the opening price. The IPO was structured as a fresh issue, raising ₹250.80 crore exclusively for the company’s expansion, acquisitions, equipment purchases, debt repayment, and general corporate purposes. There was no Offer for Sale (OFS) component, meaning existing shareholders did not sell any shares, and the proceeds directly support the company’s growth plans.
Market interest in the IPO was strong, with an overall subscription of 5.21×. Retail investors drove most of the demand, while non-institutional and qualified institutional buyers participated to a lesser extent. Strong oversubscription usually indicates confidence in a company’s business model and future performance.
Gujarat Kidney & Super Speciality Ltd operates a chain of seven mid-sized multi-speciality hospitals in Gujarat, with a total capacity of around 490 beds. The company is positioned within the healthcare services sector, which is influenced by patient demand, regulatory policies, and hospital capacity utilization. The funds raised from the IPO will help the company expand its operations, enhance infrastructure, and strengthen its presence in the regional healthcare market.
The successful listing of Gujarat Kidney & Super Speciality highlights growing investor interest in healthcare IPOs in India. The combination of a premium listing, strong retail participation, and a clear plan for fresh capital use makes this IPO a positive example for similar mid-sized healthcare companies seeking to raise funds from the public market.
In summary, the IPO debuted with a premium above the issue price, offering immediate gains to investors and providing Gujarat Kidney & Super Speciality Ltd with capital for growth. With a strong subscription, robust retail interest, and clear expansion plans, the IPO sets a promising stage for the company’s future in the regional healthcare sector.